FDA’s OK opens the door to ‘biosimilar’ drugs

Boston Herald: The Food and Drug 
Administration yesterday approved its first “biosimilar” drug — a lower-cost version of an expensive, complex medication — which could boost market competition and lead to billions of dollars in savings for insurers and patients.

Read article

Share